DBV Technologies S.A. (DBVT)

NCM – Real vaqt narxi. Valyuta: USD

16.01

-0.01 (-0.06%)

Yopilishda: Jun 26, 2026, 4:00 PM EDT

16.01

0.00 (0.00%)

Bozordan keyin: Jun 26, 2026, 4:10 PM EDT

09.06.2026

DBV Technologies Revises Participation in the Goldman Sachs 47th Annual Global Healthcare Conference

Châtillon, France, June 9, 2026 DBV Technologies Revises Participation in the Goldman Sachs 47th Annual Global Healthcare Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT) (the “Company”), a late-stage biopharmaceutical company, today announced that company management will participate in 1-on-1 investor meetings at the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026, in Miami, FL. Mr. Daniel Tassé, CEO, will not be available for the previously scheduled fireside chat due to an unavoidable disruption of planned travel to the conference.

08.06.2026

DBV Technologies to Present New Positive Data from VITESSE Study and Preview Recently Initiated THRIVE Study at the EAACI Congress 2026

Châtillon, France, June 8, 2026 DBV Technologies to Present New Positive Data from VITESSE Study and Preview Recently Initiated THRIVE Study at the EAACI Congress 2026 In the Phase 3 VITESSE study, VIASKIN® Peanut Patch demonstrated statistically significant efficacy vs. placebo in the subgroups of children with peanut allergy who also had another common atopic condition, including asthma, concomitant food allergy, or atopic dermatitis.

05.06.2026

DBV Technologies to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

Châtillon, France, June 5, 2026 DBV Technologies to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT) (the “Company”), a late-stage biopharmaceutical company, today announced that Daniel Tassé, Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026, at 9:20 AM ET, in Miami, FL. A live webcast of the fireside chat can be accessed here, and will also be available on the Events section of the Company's Investors website: https://dbv-technologies.com/investor-overview/events/, with an archived replay accessible for 90 days following the event.

03.06.2026

DBV Technologies Announces the Results of its 2026 Combined General Meeting

Châtillon, France, June 3, 2026 DBV Technologies Announces the Results of its 2026 Combined General Meeting Shareholders approved all proposed resolutions DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late stage biopharmaceutical company (the “Company”), held its Combined General Meeting (the “General Meeting”). The General Meeting was chaired by Michel de Rosen, Chairman of the Board of Directors (the “Board”).

02.06.2026

DBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN® Peanut Patch in Infants ages 6 through 12 Months with Peanut Allergy

Châtillon, France, June 2, 2026 DBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN ® Peanut Patch in Infants ages 6 through 12 Months with Peanut Allergy The study is evaluating the efficacy and safety of the VIASKIN® Peanut Patch in achieving ad lib consumption of dietary peanut in infants ages 6 through 12 months with peanut allergy First participant screened by Dr. Douglas Mack, Assistant Clinical Professor in the Department of Pediatrics at McMaster University, Ontario DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company, today announced that the first participant has been screened in the THRIVE Phase 2 clinical study evaluating the efficacy and safety of the VIASKIN® Peanut Patch in achieving ad lib consumption of dietary peanut in infants ages 6 through 12 months in achieving ad lib consumption of dietary peanut. “Recent studies such as the LEAP trial, suggest there is a critical period, or ‘window of opportunity', in food allergy treatment during which early interventions may influence the trajectory of the allergy, its management, and long-term outcomes,” said Dr. Douglas Mack, Assistant Clinical Professor in the Department of Pediatrics at McMaster University and a principal investigator of THRIVE, “Given the higher immune plasticity associated with younger patients, we are very pleased this first-of-its kind study assessing the efficacy and safety of the VIASKIN ® Peanut Patch in this very young population is now underway.

13.05.2026

Combined General Meeting of June 3, 2026

Châtillon, France, May 13, 2026 Combined General Meeting of June 3, 2026 Procedures for Obtaining Information and Preparatory Documents for the Combined General Meeting DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company (the “Company”), will hold its Combined General Meeting (the “General Meeting”) on June 3, 2026, at 10:00 a.m. CEST (04:00 a.m.

12.05.2026

DBV Technologies to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq

Châtillon, France, May 12, 2026 DBV Technologies to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT) (the “Company”), a late-stage biopharmaceutical company, today announced Daniel Tassé, Chief Executive Officer, will participate in a fireside chat at the H.C.

Videolar

No Data

There is no data to display

Press-relizlar

03.06.2026

DBV Technologies Announces the Results of its 2026 Combined General Meeting

02.06.2026

DBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN® Peanut Patch in Infants ages 6 through 12 Months with Peanut Allergy

13.05.2026

Combined General Meeting of June 3, 2026

02.04.2026

DBV Technologies S.A. (DBVT)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

DBV Technologies S.A. (DBVT)

DBV Technologies Revises Participation in the Goldman Sachs 47th Annual Global Healthcare Conference

DBV Technologies to Present New Positive Data from VITESSE Study and Preview Recently Initiated THRIVE Study at the EAACI Congress 2026

DBV Technologies to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

DBV Technologies Announces the Results of its 2026 Combined General Meeting

DBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN® Peanut Patch in Infants ages 6 through 12 Months with Peanut Allergy

Combined General Meeting of June 3, 2026

DBV Technologies to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq

Videolar

No Data

Press-relizlar

DBV Technologies Announces the Results of its 2026 Combined General Meeting

DBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN® Peanut Patch in Infants ages 6 through 12 Months with Peanut Allergy

Combined General Meeting of June 3, 2026

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of March 31, 2026

DBV Technologies Revises Participation in the Goldman Sachs 47th Annual Global Healthcare Conference

DBV Technologies to Present New Positive Data from VITESSE Study and Preview Recently Initiated THRIVE Study at the EAACI Congress 2026

DBV Technologies to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

DBV Technologies Announces the Results of its 2026 Combined General Meeting

DBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN® Peanut Patch in Infants ages 6 through 12 Months with Peanut Allergy

Combined General Meeting of June 3, 2026

DBV Technologies to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq

Videolar

No Data

Press-relizlar

DBV Technologies Announces the Results of its 2026 Combined General Meeting

DBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN® Peanut Patch in Infants ages 6 through 12 Months with Peanut Allergy

Combined General Meeting of June 3, 2026

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of March 31, 2026

Search stocks

DBV Technologies S.A. (DBVT)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

DBV Technologies S.A. (DBVT)

DBV Technologies Revises Participation in the Goldman Sachs 47th Annual Global Healthcare Conference

DBV Technologies to Present New Positive Data from VITESSE Study and Preview Recently Initiated THRIVE Study at the EAACI Congress 2026

DBV Technologies to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

DBV Technologies Announces the Results of its 2026 Combined General Meeting

DBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN® Peanut Patch in Infants ages 6 through 12 Months with Peanut Allergy

Combined General Meeting of June 3, 2026

DBV Technologies to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq

Videolar

No Data

Press-relizlar

DBV Technologies Announces the Results of its 2026 Combined General Meeting

DBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN® Peanut Patch in Infants ages 6 through 12 Months with Peanut Allergy

Combined General Meeting of June 3, 2026

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of March 31, 2026

DBV Technologies Revises Participation in the Goldman Sachs 47th Annual Global Healthcare Conference

DBV Technologies to Present New Positive Data from VITESSE Study and Preview Recently Initiated THRIVE Study at the EAACI Congress 2026

DBV Technologies to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

DBV Technologies Announces the Results of its 2026 Combined General Meeting

DBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN® Peanut Patch in Infants ages 6 through 12 Months with Peanut Allergy

Combined General Meeting of June 3, 2026

DBV Technologies to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq

Videolar

No Data

Press-relizlar

DBV Technologies Announces the Results of its 2026 Combined General Meeting

DBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN® Peanut Patch in Infants ages 6 through 12 Months with Peanut Allergy

Combined General Meeting of June 3, 2026

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of March 31, 2026